Antisense Therapeutics Limited Logo

Antisense Therapeutics Limited

ATHJF

(0.0)
Stock Price

0,01 USD

-140.38% ROA

-156.2% ROE

-3.28x PER

Market Cap.

66.916.726,85 USD

0.43% DER

0% Yield

-1170.03% NPM

Antisense Therapeutics Limited Stock Analysis

Antisense Therapeutics Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Antisense Therapeutics Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Antisense Therapeutics Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Antisense Therapeutics Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Antisense Therapeutics Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Antisense Therapeutics Limited Revenue
Year Revenue Growth
2007 762.368
2008 6.399.000 88.09%
2013 1.295.174 -394.06%
2014 1.223.926 -5.82%
2015 3.863.988 68.32%
2016 1.000.000 -286.4%
2017 69.115 -1346.86%
2018 272.424 74.63%
2019 586.788 53.57%
2020 668.433 12.21%
2021 577.764 -15.69%
2022 1.777.904 67.5%
2023 1.579.849 -12.54%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Antisense Therapeutics Limited Research and Development Expenses
Year Research and Development Expenses Growth
2007 3.372.698
2008 5.132.416 34.29%
2013 1.545.896 -232%
2014 2.146.463 27.98%
2015 1.675.820 -28.08%
2016 1.847.505 9.29%
2017 1.103.966 -67.35%
2018 975.403 -13.18%
2019 1.760.729 44.6%
2020 1.899.319 7.3%
2021 4.913.341 61.34%
2022 4.535.094 -8.34%
2023 10.162.466 55.37%
2024 26.360.028 61.45%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Antisense Therapeutics Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 1.576.531
2008 2.287.075 31.07%
2013 1.105.097 -106.96%
2014 1.015.508 -8.82%
2015 1.999.566 49.21%
2016 1.907.515 -4.83%
2017 1.974.942 3.41%
2018 939.444 -110.22%
2019 1.190.617 21.1%
2020 4.455.571 73.28%
2021 3.556.322 -25.29%
2022 2.921.237 -21.74%
2023 3.054.275 4.36%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Antisense Therapeutics Limited EBITDA
Year EBITDA Growth
2007 -4.375.030
2008 -1.112.327 -293.32%
2013 -2.458.442 54.75%
2014 -3.022.233 18.65%
2015 -16.751 -17942.1%
2016 -3.066.521 99.45%
2017 -3.212.717 4.55%
2018 -2.613.730 -22.92%
2019 -3.577.760 26.95%
2020 -6.558.692 45.45%
2021 -8.579.962 23.56%
2022 -7.522.011 -14.06%
2023 -13.249.776 43.23%
2024 -35.635.400 62.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Antisense Therapeutics Limited Gross Profit
Year Gross Profit Growth
2007 762.368
2008 6.399.000 88.09%
2013 1.071.545 -497.18%
2014 1.070.449 -0.1%
2015 3.658.635 70.74%
2016 682.617 -435.97%
2017 -138.699 592.16%
2018 266.011 152.14%
2019 581.411 54.25%
2020 560.832 -3.67%
2021 474.445 -18.21%
2022 1.688.686 71.9%
2023 1.484.650 -13.74%
2024 -128.080 1259.16%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Antisense Therapeutics Limited Net Profit
Year Net Profit Growth
2007 -4.835.963
2008 -2.136.886 -126.31%
2013 -2.454.842 12.95%
2014 -3.013.272 18.53%
2015 706.918 526.25%
2016 -2.514.443 128.11%
2017 -2.754.799 8.72%
2018 -2.331.015 -18.18%
2019 -2.944.499 20.83%
2020 -5.908.202 50.16%
2021 -8.060.639 26.7%
2022 -5.811.810 -38.69%
2023 -11.379.828 48.93%
2024 -28.703.600 60.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Antisense Therapeutics Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Antisense Therapeutics Limited Free Cashflow
Year Free Cashflow Growth
2001 0
2002 -4.110.213 100%
2003 -23.332 -17516.21%
2004 -2.227.269 98.95%
2005 -5.597.300 60.21%
2006 -3.960.091 -41.34%
2007 -2.691.263 -47.15%
2008 -3.406.021 20.99%
2009 -3.285.939 -3.65%
2010 -1.349.839 -143.43%
2011 -1.867.239 27.71%
2012 -2.419.833 22.84%
2013 -2.838.762 14.76%
2014 -3.118.501 8.97%
2015 1.268.875 345.77%
2016 -2.028.887 162.54%
2017 -2.929.797 30.75%
2018 -2.301.793 -27.28%
2019 -2.928.436 21.4%
2020 -3.955.620 25.97%
2021 -5.842.505 32.3%
2022 -7.809.079 25.18%
2023 -8.180.620 4.54%
2024 -5.278.402 -54.98%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Antisense Therapeutics Limited Operating Cashflow
Year Operating Cashflow Growth
2001 0
2002 -4.058.213 100%
2003 0 0%
2004 -2.209.608 100%
2005 -5.585.305 60.44%
2006 -3.958.499 -41.1%
2007 -2.679.528 -47.73%
2008 -3.401.498 21.23%
2009 -3.283.821 -3.58%
2010 -1.336.627 -145.68%
2011 -1.867.239 28.42%
2012 -2.405.200 22.37%
2013 -2.833.186 15.11%
2014 -3.107.886 8.84%
2015 1.268.875 344.93%
2016 -2.025.026 162.66%
2017 -2.914.222 30.51%
2018 -2.301.793 -26.61%
2019 -2.928.436 21.4%
2020 -3.945.358 25.78%
2021 -5.834.156 32.37%
2022 -7.805.166 25.25%
2023 -8.151.329 4.25%
2024 -5.281.374 -54.34%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Antisense Therapeutics Limited Capital Expenditure
Year Capital Expenditure Growth
2001 0
2002 52.000 100%
2003 23.332 -122.87%
2004 17.661 -32.11%
2005 11.995 -47.24%
2006 1.592 -653.45%
2007 11.735 86.43%
2008 4.523 -159.45%
2009 2.118 -113.55%
2010 13.212 83.97%
2011 0 0%
2012 14.633 100%
2013 5.576 -162.43%
2014 10.615 47.47%
2015 0 0%
2016 3.861 100%
2017 15.575 75.21%
2018 0 0%
2019 0 0%
2020 10.262 100%
2021 8.349 -22.91%
2022 3.913 -113.37%
2023 29.291 86.64%
2024 -2.972 1085.57%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Antisense Therapeutics Limited Equity
Year Equity Growth
2001 20.033.762
2002 13.481.712 -48.6%
2003 11.617.746 -16.04%
2004 17.132.983 32.19%
2005 10.864.344 -57.7%
2006 8.793.236 -23.55%
2007 6.017.376 -46.13%
2008 6.334.646 5.01%
2009 3.927.502 -61.29%
2010 1.344.099 -192.2%
2011 2.018.122 33.4%
2012 5.265.844 61.68%
2013 4.647.055 -13.32%
2014 2.086.891 -122.68%
2015 7.091.598 70.57%
2016 4.577.155 -54.93%
2017 1.853.423 -146.96%
2018 4.221.271 56.09%
2019 2.809.691 -50.24%
2020 4.530.989 37.99%
2021 5.727.533 20.89%
2022 21.141.439 72.91%
2023 9.975.665 -111.93%
2024 9.363.087 -6.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Antisense Therapeutics Limited Assets
Year Assets Growth
2001 20.088.222
2002 15.334.216 -31%
2003 11.982.149 -27.98%
2004 18.151.131 33.99%
2005 11.222.068 -61.74%
2006 9.116.265 -23.1%
2007 8.049.769 -13.25%
2008 9.865.525 18.41%
2009 4.989.230 -97.74%
2010 1.815.525 -174.81%
2011 2.435.861 25.47%
2012 5.689.132 57.18%
2013 5.201.156 -9.38%
2014 2.656.021 -95.83%
2015 7.673.038 65.39%
2016 5.327.359 -44.03%
2017 2.539.075 -109.81%
2018 4.802.131 47.13%
2019 3.698.530 -29.84%
2020 5.352.218 30.9%
2021 7.000.603 23.55%
2022 22.436.658 68.8%
2023 12.843.028 -74.7%
2024 14.530.294 11.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Antisense Therapeutics Limited Liabilities
Year Liabilities Growth
2001 54.460
2002 1.852.504 97.06%
2003 364.403 -408.37%
2004 1.018.148 64.21%
2005 357.724 -184.62%
2006 323.029 -10.74%
2007 2.032.393 84.11%
2008 3.530.879 42.44%
2009 1.061.728 -232.56%
2010 471.426 -125.22%
2011 417.739 -12.85%
2012 423.288 1.31%
2013 554.101 23.61%
2014 569.130 2.64%
2015 581.440 2.12%
2016 750.204 22.5%
2017 685.652 -9.41%
2018 580.860 -18.04%
2019 888.839 34.65%
2020 821.229 -8.23%
2021 1.273.070 35.49%
2022 1.295.219 1.71%
2023 2.867.363 54.83%
2024 5.167.207 44.51%

Antisense Therapeutics Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.02
Price to Earning Ratio
-3.28x
Price To Sales Ratio
38.38x
POCF Ratio
-3.7
PFCF Ratio
-3.7
Price to Book Ratio
7.15
EV to Sales
31.6
EV Over EBITDA
-2.23
EV to Operating CashFlow
-3.04
EV to FreeCashFlow
-3.04
Earnings Yield
-0.3
FreeCashFlow Yield
-0.27
Market Cap
0,07 Bil.
Enterprise Value
0,06 Bil.
Graham Number
0.07
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.89
ROE
-1.56
Return On Assets
-1.4
Return On Capital Employed
-2.65
Net Income per EBT
0.85
EBT Per Ebit
0.97
Ebit per Revenue
-14.25
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0.36
Research & Developement to Revenue
10.84
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.91
Operating Profit Margin
-14.25
Pretax Profit Margin
-13.77
Net Profit Margin
-11.7

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
-0
Capex to Revenue
0.01
Capex to Depreciation
0.09
Return on Invested Capital
-2.24
Return on Tangible Assets
-1.4
Days Sales Outstanding
525.33
Days Payables Outstanding
9152.17
Days of Inventory on Hand
0
Receivables Turnover
0.69
Payables Turnover
0.04
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.48
Current Ratio
2.81
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
9378290
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Antisense Therapeutics Limited Dividends
Year Dividends Growth

Antisense Therapeutics Limited Profile

About Antisense Therapeutics Limited

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

CEO
Dr. James Garner B.Sc (Hons),
Employee
0
Address
14 Wallace Avenue
Toorak, 3142

Antisense Therapeutics Limited Executives & BODs

Antisense Therapeutics Limited Executives & BODs
# Name Age
1 Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Chief Executive Officer, MD & Director
70
2 Ms. Deborah Ambrosini B.Com., F.C.A.
Company Secretary & Chief Financial Officer
70
3 Dr. Cathryn M. Clary M.B.A., M.D.
Chief Medical Advisor
70
4 Dr. Anthony Filippis
Chief Operating Officer
70

Antisense Therapeutics Limited Competitors